PMID- 1455403
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20100825
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 68
IP  - 5
DP  - 1992 Nov 10
TI  - Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for 
      chronic renal failure.
PG  - 563-9
AB  - The therapeutic potential of the glycosaminoglycan (GAG), dermatan sulphate (DS), 
      as an antithrombotic agent in humans has yet to be established. We have performed 
      dose ranging studies of DS to determine its effectiveness as an antithrombotic 
      agent in patients (n = 6-8) undergoing haemodialysis for chronic renal failure. 
      In an initial study, Study 1, i.v. bolus doses of 2-4 mg/kg and 5-6 mg/kg DS were 
      given to patients dialysing with polyacrylonitrile hollow fibre (PAN HF) 
      membranes. In a second crossover study, Study 2, performed using cuprophane 
      hollow fibre (CHF) membranes, i.v. bolus doses of 3 mg/kg and 6 mg/kg DS were 
      compared to a standard unfractionated heparin (UFH) regime that has been shown 
      previously to inhibit fibrin formation. Further infusion studies, Study 3 and 
      Study 4 evaluated the antithrombotic efficacy of an i.v. DS bolus of 3 mg/kg plus 
      an i.v. infusion of DS 0.6 mg kg-1 h-1 and a DS bolus of 5 mg/kg plus an infusion 
      of 1 mg kg-1 h-1 over 5 h, respectively. These studies were compared to standard 
      UFH regimes in a randomised crossover design. Plasma levels of fibrinopeptide A 
      (FPA) and thrombin-antithrombin (TAT) were used as markers of fibrin formation 
      and thrombin generation during dialysis using both membranes. The changes in DS 
      concentration following administration of the different doses were similar in 
      Studies 1 and 2. However, the effectiveness of DS as an anticoagulant appeared to 
      depend markedly on the different dialyser types used in the two studies.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Ryan, K E
AU  - Ryan KE
AD  - Department of Haematology, Charing Cross and Westminster Hospital, Hammersmith, 
      London, UK.
FAU - Lane, D A
AU  - Lane DA
FAU - Flynn, A
AU  - Flynn A
FAU - Ireland, H
AU  - Ireland H
FAU - Boisclair, M
AU  - Boisclair M
FAU - Shepperd, J
AU  - Shepperd J
FAU - Curtis, J R
AU  - Curtis JR
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (antithrombin III-protease complex)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antithrombin III/metabolism
MH  - Blood Coagulation/drug effects
MH  - Dermatan Sulfate/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Fibrinopeptide A/metabolism
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Kidney Failure, Chronic/blood/*drug therapy/*therapy
MH  - Male
MH  - Middle Aged
MH  - Peptide Hydrolases/metabolism
MH  - *Renal Dialysis
MH  - Thrombosis/prevention & control
EDAT- 1992/11/10 00:00
MHDA- 1992/11/10 00:01
CRDT- 1992/11/10 00:00
PHST- 1992/11/10 00:00 [pubmed]
PHST- 1992/11/10 00:01 [medline]
PHST- 1992/11/10 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1992 Nov 10;68(5):563-9.